# Pacira BioSciences (PCRX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PCRX
## Company Profile
- Ticker: PCRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Liposomes
## Stock Data
- Close: 23.7 USD
- Market cap: 875491309 USD
- Last updated: 2026-08-12
## Business Overview
### Non-Opioid Pain Management
Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program.
### EXPAREL
EXPAREL is a multivesicular-liposome formulation of bupivacaine that provides prolonged local or regional analgesia after surgery. It is approved for infiltration and selected nerve blocks and anchors Pacira’s commercial franchise.
### ZILRETTA
ZILRETTA is an extended-release intra-articular corticosteroid approved for osteoarthritis knee pain. A completed-enrollment Phase 3 study is evaluating expansion into osteoarthritis pain of the shoulder.
### Iovera
Iovera is a handheld device that applies controlled cold temperatures to targeted nerves for immediate, drug-free pain relief. Pacira is also pursuing a registrational indication in spasticity.
### PCRX-201
PCRX-201, or enekinragene inzadenovec, is a locally administered gene therapy in Phase 2 development for knee osteoarthritis. It uses a high-capacity adenoviral platform intended to drive local therapeutic protein expression with commercially viable manufacturing.
## Why The Stock Is Moving

As of Aug 12, 2026, PCRX closed down 2.79% at $23.70. No new same-company headline was identified in the current news window.

## Future Catalysts

- Part A Phase 2 data for PCRX-201 in knee osteoarthritis expected in 2026.
- Topline results from the Phase 3 ZILRETTA shoulder-osteoarthritis study expected by year-end 2026.
- Registrational iovera spasticity-study results expected in 2026.

## Drug Assets

- ZILRETTA

## Recent News
- 2026-08-07 12:00 EST — [Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dcb742e9) — Source: Pacira BioSciences
- 2026-08-06 12:00 EST — [Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases](https://biopharmsignal.com/news/PCRX/pacira-biosciences-announces-publication-of-positive-two-year-phase-1-data-for-p-f056da45) — Source: Pacira BioSciences
- 2026-08-04 20:01 EST — [Pacira BioSciences Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-second-quarter-2026-financial-results-fc63b776) — Source: Pacira BioSciences
- 2026-07-28 12:00 EST — [Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce](https://biopharmsignal.com/news/PCRX/pacira-biosciences-announces-new-national-survey-revealing-the-hidden-toll-of-pa-32ad8384) — Source: Pacira BioSciences
- 2026-07-27 12:00 EST — [Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process](https://biopharmsignal.com/news/PCRX/pacira-biosciences-advances-pcrx-201-development-program-with-successful-transit-5e500af3) — Source: Pacira BioSciences